What it isChelator of copper and heavy metals; Wilson disease, cystinuria and lead poisoning.
Why this oneIt is the long-established oral treatment for Wilson disease and reduces cystine stone formation.
What limits itParadoxical neurological worsening early in Wilson disease. Myelosuppression, proteinuria and drug-induced autoimmunity; pyridoxine is co-given.
BOXED WARNING Serious, potentially fatal toxicity; use only under close, continuous physician supervision and warn patients to report toxicity promptly.
FDA dosing
Population
Start
Target
Max
Wilson's disease
adult
250 mg QD (if intolerant) up to 750 mg-1.5 g/day
0.75-1.5 g/day
2 g/day
Cystinuria
adult
250 mg QD, increase gradually
2 g/day QID
4 g/day
Cystinuria
pediatric
30 mg/kg/day divided QID
Rheumatoid arthritis
adult
125-250 mg QD
500-750 mg/day
~1.5 g/day
Titration RA: increase by 125-250 mg/day at 1-3 month intervals.
Renal Undefined
Hepatic Undefined
Doses <=500 mg/day may be given once daily; >500 mg/day must be divided.
Instructions
Take on empty stomach, >=1 h before or 2 h after meals, and >=1 h apart from any other drug, food, or milk
Supplement pyridoxine (increased requirement)
Cystinuria: drink copiously incl. ~1 pint at bedtime and once overnight; retain bedtime dose if reducing
After interrupted therapy, reintroduce cautiously at a lower dose
Contraindications
Pregnancy (except Wilson's disease or certain cystinuria patients)
Nursing mothers should not breastfeed during therapy
Prior penicillamine-related aplastic anemia or agranulocytosis (do not restart)
Rheumatoid arthritis patients with history/evidence of renal insufficiency